AM6206

AM6206 is a preclinical-stage, orally available small molecule drug candidate being developed by MAK Scientific. It is part of a pipeline focused on modulating the endocannabinoid system to treat various conditions, including chronic liver disease, metabolic disorders, and neurodegenerative diseases. While the specific molecular target within the endocannabinoid system—such as cannabinoid receptors (CB1, CB2) or enzymes like fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL)—has not been explicitly disclosed for this compound, it is designed for oral administration to address unmet needs in inflammatory and metabolic pathologies.